Atyr Pharma Inc. (NASDAQ:LIFE) posted its quarterly earnings data on Monday. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.09.

Atyr Pharma (NASDAQ:LIFE) opened at 3.50 on Tuesday. Atyr Pharma has a 1-year low of $2.48 and a 1-year high of $10.93. The company’s 50-day moving average price is $2.95 and its 200 day moving average price is $3.05. The firm’s market capitalization is $83.01 million.

Earnings History for Atyr Pharma (NASDAQ:LIFE)

Several large investors have recently bought and sold shares of the company. A.R.T. Advisors LLC boosted its stake in Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock valued at $108,000 after buying an additional 18,410 shares during the period. Bridgeway Capital Management Inc. acquired a new stake in Atyr Pharma during the second quarter valued at about $133,000. Emerald Acquisition Ltd. boosted its stake in Atyr Pharma by 43.2% in the third quarter. Emerald Acquisition Ltd. now owns 106,410 shares of the company’s stock valued at $339,000 after buying an additional 32,100 shares during the period. BlackRock Advisors LLC boosted its stake in Atyr Pharma by 14,820.9% in the second quarter. BlackRock Advisors LLC now owns 244,405 shares of the company’s stock valued at $679,000 after buying an additional 242,767 shares during the period. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in Atyr Pharma by 317.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 344,214 shares of the company’s stock valued at $957,000 after buying an additional 261,753 shares during the period. Institutional investors and hedge funds own 44.63% of the company’s stock.

LIFE has been the topic of several research analyst reports. BMO Capital Markets set a $8.00 price objective on Atyr Pharma and gave the company a “hold” rating in a report on Thursday, October 6th. Citigroup Inc. boosted their price objective on Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday, August 16th. Zacks Investment Research downgraded Atyr Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, October 12th. Finally, JPMorgan Chase & Co. cut their price objective on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Atyr Pharma presently has an average rating of “Hold” and an average target price of $6.50.

About Atyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

5 Day Chart for NASDAQ:LIFE

Receive News & Stock Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related stocks with our FREE daily email newsletter.